Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
Public ClinicalTrials.gov record NCT01696396. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Crohn's Disease
Study identification
- NCT ID
- NCT01696396
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Amgen
- Industry
- Enrollment
- 254 participants
Conditions and interventions
Conditions
Interventions
- Abrilumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 3, 2012
- Primary completion
- Dec 25, 2014
- Completion
- Apr 9, 2018
- Last update posted
- Jun 26, 2019
2012 – 2018
United States locations
- U.S. sites
- 24
- U.S. states
- 16
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35216 | — |
| Research Site | Dothan | Alabama | 36305 | — |
| Research Site | Mobile | Alabama | 36608 | — |
| Research Site | Goodyear | Arizona | 85395 | — |
| Research Site | Phoenix | Arizona | 85012 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Jacksonville | Florida | 32256 | — |
| Research Site | Sanford | Florida | 32771 | — |
| Research Site | Atlanta | Georgia | 30342 | — |
| Research Site | Arlington Heights | Illinois | 60005 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Chesterfield | Michigan | 48047 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | Mexico | Missouri | 65265 | — |
| Research Site | Great Neck | New York | 11021 | — |
| Hospital | New York | New York | 10029 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | Charlotte | North Carolina | 28210 | — |
| Research Site | Greenville | North Carolina | 27834 | — |
| Research Site | Mentor | Ohio | 44060 | — |
| Research Site | Oklahoma City | Oklahoma | 73103 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Germantown | Tennessee | 38138 | — |
| Research Site | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 60 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01696396, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 26, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01696396 live on ClinicalTrials.gov.